The Phase 3 trial investigating Sarclisa® in combination with carfilzomib, lenalidomide and dexamethasone showed a statistically significant improvement in the rate of minimal residual disease negativity, compared with KRd alone.
The Phase 3 trial investigating Sarclisa® (isatuximab) in combination with carfilzomib, lenalidomide and dexamethasone (KRd) showed a statistically significant improvement in the rate of minimal residual disease (MRD) negativity, compared with KRd alone, after autologous stem cell transplant (ASCT) consolidation…